Pharmacodynamics limitations

Another concern is the coinfusion of intravenous medications with PN admixtures. Many intravenous medications have limited compatibility with 3-in-l formulations but may be coinfused with a 2-and-l formulation.23,24 Some medications can be coinfused at the Y-site, few medications can be mixed directly into the PN solution or coinfused with intravenous lipid emulsion, and some cannot be mixed or coinfused with the PN admixture.23,24 Always consult compatibility data before adding a medication to a PN admixture or coinfusing with PN. Medications that are compatible should be added to PN only if it is reasonable and safe (i.e., based on toxicity profile, pharma-cokinetic/pharmacodynamic considerations). 

Polycyclic Aromatic Hydrocarbon Physiologically Based Pharmacodynamic Physiologically Based Pharmacokinetic polychromatic erythrocytes permissible exposure limit photo ionization detector picogram picomole... 

Within the medical community it has been acknowledged that elderly patients often respond to drug therapy differently from their younger counterparts. Aside from alteration of various pharmacokinetic and pharmacodynamic processes, elderly patients tend to suffer from a number of chronic conditions and, thus, have more complex dosage regimens. Additionally, a variety of physical limitations prevalent among the elderly may hinder their ability to self-administer medication. 

In order to overcome the limitations of the above drugs, a series of rifamycin derivatives with improved pharmacokinetic (i.e. virtually absence of GI absorption) and pharmacodynamic (i.e. with broad spectrum of antibacterial activity) properties have been synthesized at Alfa Wassermann laboratories [33]. Amongst the different molecules, the compound marked L-105 and later... 

Only a limited number of chemicals evoke a local quantifiable pharmacodynamic response, for example, the concentration-dependent vasoconstriction effect of corticosteroids. In these experiments, resulting skin blanching is scored visually by one or more qualified investigators, using an ordinal data scale. The lack of instrumentation has been criticized, because of possible subjective errors [25], However, approaches using the Chromameter device, although recommended by the FDA, have failed to return the desired precision [26, 27],... 

Doses selected for safety pharmacology studies are typically based on the criteria established in the ICH S7A guidance.25 Doses should exceed those projected for clinical efficacy and at the upper limit be bound by (1) adverse pharmacodynamic effects in the safety pharmacology study (2) moderately adverse effects in other non-clinical studies that follow a similar route and duration of dosing or (3) limit of solubility/toxicity. In the absence of adverse effects, the maximum administrable dose can be used. If nonreusable animals enter the study, then the maximum tolerated dose may be appropriate. Most importantly, the doses/concentrations should establish the dose/concentration-response relationship of the adverse effect. 

The ICH S7A guidance states that "supplemental" studies are meant to evaluate potential adverse pharmacodynamic effects on organ systems functions that are not acutely essential for the maintenance of human life and not addressed by the "core battery" or repeated dose toxicity studies when there is a cause for concern.25 Examples of physiological functions that fall into that category include, but are not limited to, the renal/urinary, immune, GI, endocrine and autonomic nervous systems. This section focuses on the renal and GI systems based on their potential impact on the clinical development program. 

S Dose levels in vivo It is necessary to define the dose-response relationship of any adverse effects observed. The onset and duration of effects should be measured. Because there are differences in sensitivity between species, the doses chosen need to exceed those used for therapy. The ICH guideline states that the highest dose tested should be a dose that produces moderate adverse effects, for example, dose-limiting pharmacodynamic effects or other toxicities. Such effects should not be so severe that they confoimd the interpretation of the results being sought. Safety pharmacology studies... 

Limiting pharmacodynamic effects (e.g. a dose which sedates the animals)... 

The number of subjects per cohort needed for the initial study depends on several factors. If a well established pharmacodynamic measurement is to be used as an endpoint, it should be possible to calculate the number required to demonstrate significant differences from placebo by means of a power calculation based on variances in a previous study using this technique. However, analysis of the study is often limited to descriptive statistics such as mean and standard deviation, or even just recording the number of reports of a particular symptom, so that a formal power calculation is often inappropriate. There must be a balance between the minimum number on which it is reasonable to base decisions about dose escalation and the number of individuals it is reasonable to expose to a NME for the first time. To take the extremes, it is unwise to make decisions about tolerability and pharmacokinetics based on data from one or two subjects, although there are advocates of such a minimalist approach. Conversely, it is not justifiable to administer a single dose level to, say, 50 subjects at this early stage of ED. There is no simple answer to this, but in general the number lies between 6 and 20 subjects. 

A comprehensive knowledge of all the preclin-ical information about a compound is an essential requirement for the safe conduct of the first study in man. Toxicology, metabolism, pharmacokinetics and pharmacodynamics are all important despite their limited predictive power for man. As explained above, the study design must take the findings into account. 

A number of limitations related to PK/PD modeling are also a reality in situations where predictability of the animal model to man is questionable, where the time course of the pharmacodynamic effect cannot be assessed for drug candidates and when, for example, no accessible/ valid pharmacodynamic endpoint for PK/PD is available. The relevance of the animal model for human could be addressed to some extent at least by measuring relative potency in animal versus man in vitro. In situations where no relevant PD endpoint is available (e.g., for CNS efficacy models), effects at target level (i.e., enzyme inhibition, receptor occupancy) might represent a valuable alternative. In this context however the level and duration of target effect required for clinical efficacy requires careful considerations. 

Generally, the dihydropyridine CCBs have evolved into three distinct subclasses based on their pharmacokinetics and pharmacodynamics. Early dihydropyridines such as nifedipine and nicardipine are characterized by a rapid onset of action and short duration of action due to limited half-life lives, thus requiring twice-daily dosing (Bayer, 2004). In addition, these short-acting compounds may have potential detrimental effects... 

II.e.5.1. Background. The most important drug interactions result from pharmacokinetic (PK) phenomena. Pharmacodynamic (PD) interactions are poorly understood in humans (receptor level interaction potentiation of effect by action on different targets). Classically, PK interactions occur at the enzyme level. Careful attention to this factor should help limit the incidence of adverse effects, make it easier to maintain plasma levels within the therapeutic range, and demonstrate the benefit of certain therapeutic combinations. Clinical trials on add-on regimens are needed. It should be noted that the clinical relevance of certain PK interactions remains to be established. 

Limitations of semm levels pharmacokinetic parameters determined in blood are not closely indicative of the situation in the central compartment (here the CNS) serum levels are not correlated with activity (pharmacodynamics) in general, only the mother molecule is assayed although its metabolites may be active or toxic the relationship between concentration (PK) and activity (PD) is often complex assays of free forms would be more pertinent. 

Research on drug interactions with zolpidem and zaleplon is limited, but any drug with CNS depressant effects could potentially enhance the CNS depressant effects of zolpidem and zaleplon through pharmacodynamic interactions. In addition, zolpidem is primarily metabolized by CYP 3A3/4, and zaleplon is partially metabolized by CYP 3A3/4. Thus, inhibitors of these enzymes may increase blood levels and the toxicity of zolpidem. 

Goldstein A Brown BW (2003). Urine testing in methadone maintenance treatment applications and limitations. Journal of Substance Abuse Treatment, 25, 61-3 Gonzalez JP Brogden RN (1988). Naltrexone a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 35, 192-213... 

---